These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 15801868)

  • 1. Histrelin Hydrogel Implant--Valera: Histrelin implant, LHRH-Hydrogel implant, RL 0903, SPD 424.
    Drugs R D; 2005; 6(1):53-5. PubMed ID: 15801868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The histrelin implant: a novel treatment for central precocious puberty.
    Hirsch HJ; Gillis D; Strich D; Chertin B; Farkas A; Lindenberg T; Gelber H; Spitz IM
    Pediatrics; 2005 Dec; 116(6):e798-802. PubMed ID: 16322137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abarelix: abarelix-depot-F, abarelix-depot-M, abarelix-L, PPI 149, R 3827.
    Drugs R D; 2003; 4(3):161-6. PubMed ID: 12757402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics and treatment patterns with histrelin acetate subcutaneous implants vs. leuprolide injections in children with precocious puberty: a real-world study using a US claims database.
    Silverman LA; Han X; Huang H; Near AM; Hu Y
    J Pediatr Endocrinol Metab; 2021 Aug; 34(8):961-969. PubMed ID: 34147047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Histrelin acetate--the first once yearly LHRH agonist].
    Altarac S
    Lijec Vjesn; 2011; 133(9-10):320-2. PubMed ID: 22165080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
    Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial.
    Eugster EA; Clarke W; Kletter GB; Lee PA; Neely EK; Reiter EO; Saenger P; Shulman D; Silverman L; Flood L; Gray W; Tierney D
    J Clin Endocrinol Metab; 2007 May; 92(5):1697-704. PubMed ID: 17327379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Continuous Suppression With Once-Yearly Histrelin Subcutaneous Implants for the Treatment of Central Precocious Puberty: A Final Report of a Phase 3 Multicenter Trial.
    Silverman LA; Neely EK; Kletter GB; Lewis K; Chitra S; Terleckyj O; Eugster EA
    J Clin Endocrinol Metab; 2015 Jun; 100(6):2354-63. PubMed ID: 25803268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histrelin for central precocious puberty-a single surgeon experience.
    Rosati S; Maarouf R; Brown K; Poppe M; Parrish D; Haynes J; Lanning D
    J Surg Res; 2015 Oct; 198(2):355-9. PubMed ID: 25899147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ISA 247: trans-ISA 247, trans-R 1524, ISA(TX)247, ISAtx 247, ISATx247, LX 211, LX211, R 1524, R-1524.
    Drugs R D; 2007; 8(2):103-12. PubMed ID: 17324008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time to menarche and final height after histrelin implant treatment for central precocious puberty.
    Gillis D; Karavani G; Hirsch HJ; Strich D
    J Pediatr; 2013 Aug; 163(2):532-6. PubMed ID: 23485026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective long-term androgen suppression in men with prostate cancer using a hydrogel implant with the GnRH agonist histrelin.
    Schlegel PN; Kuzma P; Frick J; Farkas A; Gomahr A; Spitz I; Chertin B; Mack D; Jungwirth A; King P; Nash H; Bardin CW; Moo-Young A
    Urology; 2001 Oct; 58(4):578-82. PubMed ID: 11597543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histrelin: in advanced prostate cancer.
    Deeks ED
    Drugs; 2010 Mar; 70(5):623-30. PubMed ID: 20329807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Free alpha-subunit is the most sensitive marker of gonadotropin recovery after treatment of central precocious puberty with the histrelin implant.
    Hirsch HJ; Lahlou N; Gillis D; Strich D; Rosenberg-Hagen B; Chertin B; Farkas A; Hartman H; Spitz IM
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2841-4. PubMed ID: 20339028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single histrelin implant is effective for 2 years for treatment of central precocious puberty.
    Lewis KA; Goldyn AK; West KW; Eugster EA
    J Pediatr; 2013 Oct; 163(4):1214-6. PubMed ID: 23809043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy and tolerability of once-yearly histrelin acetate subcutaneous implant in patients with advanced prostate cancer.
    Shore N; Cookson MS; Gittelman MC
    BJU Int; 2012 Jan; 109(2):226-32. PubMed ID: 21851539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experience with the once-yearly histrelin (GnRHa) subcutaneous implant in the treatment of central precocious puberty.
    Lewis KA; Eugster EA
    Drug Des Devel Ther; 2009 Sep; 3():1-5. PubMed ID: 19920916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experience with the Histrelin Implant in Pediatric Patients.
    Eugster EA
    Endocr Dev; 2016; 30():54-9. PubMed ID: 26683629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
    Chertin B; Spitz IM; Lindenberg T; Algur N; Zer T; Kuzma P; Young AJ; Catane R; Farkas A
    J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.